NET Tumor of the EG Junction

Home › Forums › Edits › Vendor and Central Registry Metafile Administrators › NET Tumor of the EG Junction

Viewing 1 post (of 1 total)
  • Author
    Posts
  • November 16, 2016 at 8:01 pm #3278
    Anonymous[email protected]
    Spectator

    Per the official response on the CAnswer Forum, a site histology combination of EGJunction and neuroendocrine carcinoma is unstageable for AJCC 7. Based on Site Histology combinations of C160 and 8246/3, the primary can be staged with the NET Chapter and Schema. If the response is indeed correct, it will need to be addressed beyond edits, as the schema discriminator will need to be required for NET tumors. This will also affect software DLLs.

    A quick query and manual review shows very low frequency of this exact situation. A more thorough analysis could be done upon request if needed.

  • Author
    Posts
Viewing 1 post (of 1 total)
  • The forum ‘Vendor and Central Registry Metafile Administrators’ is closed to new topics and replies.

Recent Topics

Funding for this web site content was made possible in part by a contract with Federal funds from the National Cancer Institute, National Institutes of Health and Department of Health & Human Services under Contract number 75N91021D00018 / 75N91021F00001. Additionally, funding for this web site content was made possible in part by a cooperative agreement with Federal funds from the Centers for Disease Control and Prevention Cooperative Agreement number 1NU58DP007575. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCI and CDC.

Copyright © 2018 NAACCR, Inc. All Rights Reserved | naaccr-swoosh-only See NAACCR Partners and Sponsors